There are now multiple immunotherapies targeting clearance
of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the
next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell
initiative, put together by Jeanne Loring — a
researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi
of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.